Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Verity

Drug and asset intelligence for Verity with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
2
Stage
Development stage unavailable

Mechanism of action

Hormonal Therapy

Recent signals(2)

RegulatoryJuly 3, 2026

FDA Approves Supplemental Applications for TRELSTAR

The FDA has approved supplemental applications for TRELSTAR, a triptorelin pamoate product.

RegulatoryJuly 1, 2026

FDA Accepts Supplemental NDA for TRELSTAR by Verity

The FDA has accepted a supplemental NDA for TRELSTAR, an injectable formulation of triptorelin pamoate.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Verity

Monitor for any upcoming market launches or additional indications related to TRELSTAR.

July 3, 2026 · N/A

Topline Data

— Verity

Monitor for further updates on the approval timeline and any upcoming data presentations related to TRELSTAR.

July 1, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Hormonal Therapy →
Oncology →
Oncology · Hormonal Therapy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.